Fortive Corporation (FTV) SEC Filings & Earnings Calls
EquiReason read 12 Fortive Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-09-10 — Fortive appointed Susan L. Main to the Board of Directors and Audit Committee, effective September 9, 2026..
Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason
- Market cap
- 18.2B
- P/E TTM
- 35.7
- Dividend yield
- 0.3%
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
29 Jul 20268-K · 2.02Revenue $1.10B (+8% y/y); Core revenue growth 6.7; Adjusted diluted EPS $0.74 (+28% y/y); Guidance: FY2026 adjusted EPS $2.95-$3.05earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.10B | +8% y/y |
| Core revenue growth · Q2-2026 | 6.7% | |
| Adjusted diluted EPS · Q2-2026 | $0.74 | +29% y/y |
| Adjusted EBITDA margin · Q2-2026 | 29.5% | |
| GAAP diluted EPS · Q2-2026 | $0.51 | +55% y/y |
| Free cash flow · Q2-2026 | $271M | +50% y/y |
| Operating cash flow · Q2-2026 | $299M | +46% y/y |
| Intelligent Operating Solutions revenue · Intelligent Operating Solutions · Q2-2026 | $758M | +9% y/y |
| Advanced Healthcare Solutions revenue · Advanced Healthcare Solutions · Q2-2026 | $339M | +6% y/y |
Guidance
FY2026 adjusted EPS $2.95-$3.05
Raising FY2026 adjusted EPS guidance reflecting strong first-half performance and confidence in trajectory.
Risks flagged
Advanced Healthcare Solutions segment margin declined 80bps YOY.
“Advanced Healthcare Solutions adj. EBITDA margin 26.1% vs 26.9% prior year, down 80bps”
Precision Technologies separation completed; no further impact from discontinued operations.
“Precision Technologies separation completed on June 28, 2025”
29 Jul 202610-QFortive reported strong Q2 2026 results: core revenue growth 6.7%, operating margin expanded 240bps to 19.1%.earningsopen
Figures in the filing · each found in the filing text
| Core Revenue Growth · Q2-2026 | 6.7% | |
| Operating Profit Margin · Q2-2026 | 19.1% | |
| IOS Operating Profit · IOS · Q2-2026 | $204M | +19% y/y |
| IOS Operating Margin · IOS · Q2-2026 | 26.8% | |
| AHS Operating Profit · AHS · Q2-2026 | $38M | +7% y/y |
| AHS Operating Margin · AHS · Q2-2026 | 11.3% | |
| Gross Profit Margin · Q2-2026 | 63.4% | |
| Operating Cash Flow · H1-2026 | $519M | +31% y/y |
| Free Cash Flow · H1-2026 | $464M | +32% y/y |
| Capital Expenditures · H1-2026 | $55M | +19% y/y |
Risks flagged
Tariff uncertainty
“Impacts of the IEEPA Ruling and any new responsive tariffs, including our ability to mitigate fully any such new tariffs, are uncertain.” · word for word
Foreign exchange volatility
“Comprehensive income decreased by $114 million during the second quarter as compared to the comparable period in 2025 due to unfavorable changes in foreign currency translation of $105 million.” · word for word
Geopolitical risks
“ongoing geopolitical events; wars and hostilities in the Middle East and in Ukraine, including the corresponding impact on energy costs, interest rates, cybersecurity, international trade, and global economic conditions” · word for word
14 May 20268-K · 1.01, 2.03, 8.01Fortive issued $1.1B in senior notes (4.750% 2031, 5.250% 2036) to refinance maturing debt and for general corporate purposes.open
Risks flagged
Increased debt load may impact leverage ratios and interest expense.
“The notes are the Company’s general unsecured obligations”
30 Apr 20268-K · 2.02Revenue $1.07B (+8% y/y); Core revenue growth 5.3; GAAP Net Earnings $136M (+21% y/y); Guidance: FY 2026 adjusted EPS $2.90-$3.00, trending upper halfearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.07B | +8% y/y |
| Core revenue growth · Q1-2026 | 5.3% | |
| GAAP Net Earnings · Q1-2026 | $136M | +21% y/y |
| Adjusted EBITDA · Q1-2026 | $314M | +13% y/y |
| Adjusted EBITDA margin · Q1-2026 | 29.3% | |
| GAAP diluted net EPS · Q1-2026 | $0.44 | +33% y/y |
| Adjusted diluted net EPS · Q1-2026 | $0.70 | +25% y/y |
| Free Cash Flow · Q1-2026 | $194M | +14% y/y |
| Intelligent Operating Solutions revenue · Intelligent Operating Solutions · Q1-2026 | $743M | +8% y/y |
| Advanced Healthcare Solutions revenue · Advanced Healthcare Solutions · Q1-2026 | $326M | +8% y/y |
Guidance
FY 2026 adjusted EPS $2.90-$3.00, trending upper half
Strong Q1 beat with core growth and margin expansion; reaffirmed FY guidance with upward bias.
30 Apr 202610-QRevenue $1.07B (+8% y/y); Gross profit margin 63.2; Operating profit margin 17.9open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.07B | +8% y/y |
| Gross profit margin · Q1-2026 | 63.2% | |
| Operating profit margin · Q1-2026 | 17.9% | |
| Core revenue growth · Q1-2026 | 5.3% | |
| Operating cash flow · Q1-2026 | $220M | +15% y/y |
| Capital expenditures · Q1-2026 | $27M | +26% y/y |
| IOS Revenue · IOS · Q1-2026 | $743M | +8% y/y |
| IOS Operating profit margin · IOS · Q1-2026 | 25.1% | |
| AHS Revenue · AHS · Q1-2026 | $326M | +8% y/y |
| AHS Operating profit margin · AHS · Q1-2026 | 10.0% |
Risks flagged
Tariff input cost pressure
“the unfavorable net impact of tariffs and related countermeasures” · word for word
Foreign exchange volatility
“Currency exchange rates (2.4) %” · word for word
29 Apr 2026DEF 14ACEO and CFO transitions completed; Ralliant separation executed; proxy discloses compensation structure and pay-for-performance alignment.open
Figures in the filing · each found in the filing text
| Free Cash Flow · FY2025 | $931M | |
| Core Revenue Growth · H2-2025 | 2.0% | |
| Adjusted EBITDA Growth · H2-2025 | 9.0% | |
| Adjusted EPS Growth · H2-2025 | 13.0% | |
| Adjusted EPS · FY2025 | $2.71 | |
| Net Income · FY2025 | $533M | |
| Share Repurchases · FY2025 | $1.60B | |
| Adjusted EBITDA Margin · H2-2025 | 31.0% | |
| Scope 1 and 2 GHG Emissions Reduction · FY2025 | 51.4% |
25 Feb 202610-KRisks named: Tariff and Trade Policy Uncertainty, Foreign Exchange Risk, AI Implementation Riskopen
Risks flagged
Tariff and Trade Policy Uncertainty
“Recent economic, foreign and political policies and enforcement actions, including trade restrictions, withdrawal from global trade agreements, uncertainty relating to the future rate or enforceability of tariffs and reciprocal tariffs, including as a result of the recent ruling by the Supreme Court of the United States invalidating certain tariffs previousl” · word for word
Foreign Exchange Risk
“Overall strengthening of the U.S. dollar during most of fiscal year 2025 has increased the effective price of our products sold in U.S. dollars into other countries, which may require us to lower our prices or adversely affect sales to the extent we do not increase local currency prices.” · word for word
AI Implementation Risk
“There are significant risks involved in developing and deploying AI and there can be no assurance that the usage of AI will enhance our products or services or be beneficial to our business, including our efficiency or profitability.” · word for word
4 Feb 20268-K · 2.02Revenue $1.12B (+5% y/y); Core revenue growth 3.3; GAAP Net Income $192M (-1% y/y); Guidance: FY2026 adjusted EPS guidance $2.90-$3.00earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $1.12B | +5% y/y |
| Core revenue growth · Q4-2025 | 3.3% | |
| GAAP Net Income · Q4-2025 | $192M | -1% y/y |
| Adjusted EBITDA · Q4-2025 | $358M | +8% y/y |
| Adjusted diluted EPS · Q4-2025 | $0.90 | +13% y/y |
| Free Cash Flow · Q4-2025 | $314M | +3% y/y |
| Intelligent Operating Solutions Revenue · Intelligent Operating Solutions · Q4-2025 | $770M | +5% y/y |
| Advanced Healthcare Solutions Revenue · Advanced Healthcare Solutions · Q4-2025 | $353M | +3% y/y |
Guidance
FY2026 adjusted EPS guidance $2.90-$3.00
Initiated FY2026 adjusted EPS guidance above FY2025 actuals, reflecting confidence in growth and margin expansion.
Risks flagged
Advanced Healthcare Solutions segment margin declined 150 bps.
“Advanced Healthcare Solutions: Adj. EBITDA margin 26.0% vs 27.5% last year, down 150 bps.”
29 Oct 202510-QFortive reported Q3 2025 results with core revenue growth of 1.9%, driven by pricing, but volume declined and margins compressed.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.03B | +2% y/y |
| Core Revenue Growth · Q3-2025 | 1.9% | |
| Gross Profit Margin · Q3-2025 | 63.2% | |
| Operating Profit Margin · Q3-2025 | 15.5% | |
| Operating Cash Flow · 9M-2025 | $692M | -1% y/y |
| Free Cash Flow · 9M-2025 | $617M | -3% y/y |
| IOS Revenue · Intelligent Operating Solutions · Q3-2025 | $699M | +3% y/y |
| AHS Revenue · Advanced Healthcare Solutions · Q3-2025 | $328M | +2% y/y |
| Share Repurchases · 9M-2025 | $1.35B | +218% y/y |
Risks flagged
Volume decline persists
“Volume declined modestly driven by reduced demand for sterilization equipment due to uncertainty surrounding hospital responses to recent changes in healthcare policy.” · word for word
Tariff impact on margins
“Unfavorable impact from tariffs net of countermeasures.”
Healthcare policy uncertainty
“Volume declined modestly driven by reduced demand for sterilization equipment due to uncertainty surrounding hospital responses to recent changes in healthcare policy.” · word for word
29 Oct 20258-K · 2.02Revenue $1.03B (+2% y/y); Core revenue growth 1.9; GAAP net income $117M (+5% y/y); Guidance: Adjusted diluted EPS guidance raised to $2.63-$2.67 from $2.50-$2.60earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.03B | +2% y/y |
| Core revenue growth · Q3-2025 | 1.9% | |
| GAAP net income · Q3-2025 | $117M | +5% y/y |
| Adjusted EBITDA · Q3-2025 | $309M | +10% y/y |
| Adjusted diluted net EPS · Q3-2025 | $0.68 | +15% y/y |
| GAAP diluted net EPS · Q3-2025 | $0.35 | +9% y/y |
| Free cash flow · Q3-2025 | $266M | -6% y/y |
| Intelligent Operating Solutions revenue · Intelligent Operating Solutions · Q3-2025 | $699M | +3% y/y |
| Advanced Healthcare Solutions revenue · Advanced Healthcare Solutions · Q3-2025 | $328M | +2% y/y |
| Intelligent Operating Solutions adjusted EBITDA margin · Intelligent Operating Solutions · Q3-2025 | 34.6% |
Guidance
Adjusted diluted EPS guidance raised to $2.63-$2.67 from $2.50-$2.60
Full year 2025 adjusted diluted EPS guidance raised by ~5% at midpoint, reflecting strong Q3 performance and confidence in Fortive Accelerated strategy
Risks flagged
Precision Technologies separation completed
“Completed separation of Precision Technologies segment on June 28, 2025”
Fortive Corporation — questions
- What did Fortive Corporation file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-09-10 — Fortive appointed Susan L. Main to the Board of Directors and Audit Committee, effective September 9, 2026.
Every figure on this page comes from Fortive Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.